Trial Profile

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oprozomib (Primary) ; Midazolam
Indications Haematological malignancies; Multiple myeloma; Solid tumours
Focus Pharmacokinetics
Sponsors Amgen

Most Recent Events

18 Feb 2021 Status changed to discontinued , according to clinicalTrials.gov record.
02 Jul 2019 Planned End Date changed from 12 Jun 2019 to 10 Jul 2019.
14 Mar 2019 Planned End Date changed from 30 Jun 2019 to 12 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com